Easton Pharmaceuticals, Inc designs, produces, and sells premium health care products. Most of them use the proprietary transdermal gel formulation that the Canadian company has developed. In 2013, Easton Pharma also announced that it has begun breaking into the medical marijuana sector.
The company was founded in 1997 and originally operated as LAM Pharmaceutical Corp. It became Easton Pharmaceuticals, Inc in 2010.
With a market cap pegged at USD 1.26 M, Easton Pharmaceuticals currently trades in the OTC markets as EAPH.
Products of the company are targeted towards various health issues. Most are applied topically but have transdermal effects due to Easton’s unique proprietary delivery system. There is the arthritis- and body-pain reliever Kenestrin Gel, the anti-wrinkle cream Skin Renou HA, the female sexual enhancement gel Viorra, and the motion sickness reliever gel Nauseasol.
In addition, Easton Pharmaceuticals is working on two major products in its pipeline. These are the early-stage cancer drug called XILIVE and the transdermal treatment for Female Sexual Arousal Disorder (FSAD) called Femlife.
For its entry into the marijuana industry, Easton Pharmaceuticals revealed its intention to establish medical marijuana clinics in Canada and the US. It has also started to discuss investment proposals, such as the one with a Michigan-based medical marijuana dispensary.
The company’s biggest move so far on this front is its investment in AMFIL Technologies. AMFIL is the manufacturer of a plant-growing system called the mPact-GROzone Antimicrobial System, whose technologies reduce pathogens and pests inside cannabis grow facilities.
Easton Pharmaceuticals, Inc is led by CEO and President Carla Pepe, CFO John Adams, COO Kent A Deuters, Treasurer Dr. Peter J. Rothbart, and Chief Marketing and Technology Officer Dr. Lilla Albert. Alongside them is Dr. Daniel Bagi as the Senior Executive Physician Consultant.
Yahoo! Finance: EAPH News
Latest Financial News for EAPH
Easton realized revenues of $378,589 USD during 2018, an increase in revenues over 145% from 2017. The Company's revenues primarily derived during the last 2 quarters from activities generated from its Georgina property, as well as from its construction contract to frame 150 new homes, through its Real Estate and Development Division. Easton's management announced last year that it would be entering into additional lucrative market segments that its directors have experience in.
TORONTO, ON / ACCESSWIRE / March 13, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Provides Update on Its $2,600,000 CDN framing contract to build approximately 150 homes just outside of Toronto, Ontario, including an update on its development project to construct upto 42 new homes on an approximately 2.7 acres property it recently acquired in Cobourg, Ontario. Easton recently announced that it has entered into a $2,600,000 CDN framing contract and has commenced work on the framing of approximately 150 homes with a well-known prominent regional builder. Easton received approximately $275,000 CDN during its last quarter (October to December 2018) in payments from its framing contract of 150 homes and has received a further $300,000 CDN in payments for the months of January and February 2019 so far.
TORONTO, ON / ACCESSWIRE / March 11, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH ) announces that it has commenced the set-up of a Cannabis Edibles division, pursuant to its acquisition of a commercial ...
CORAL GABLES, FL / ACCESSWIRE / March 5, 2019 / The marijuana stock market has largely benefited from the ability of states to enact their own cannabis legislation, resulting in the majority of U.S. states having some form of legalized cannabis usage. Despite states operating with autonomy in terms of cannabis legalization, there are still a considerable amount of states that have yet to get on board. As we continue to move through the month of March, as lawmakers advocate for favorable cannabis legislation, this will hopefully translate to investors taking interest in the cannabis industry.
In its ongoing efforts to diversify and enter other lucrative sectors and add value-added businesses to achieve consistent growing sales to coincide with its revenue-generating framing contract and its pharmaceutical / diagnostic division, Easton is pleased to have signed an agreement to acquire a Toronto based commercial bakery and food preparation company which manufactures white labeled food products for third party food companies and its own line of niche food product lines, sold in major grocery chains, as well as specialty coffee chains. The company has an R&D division with product development and has begun discussions with licensed producers of cannabis, as well as food chains in order to develop and supply cannabis edible products.
